Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters
用于定义仓鼠急性 SARS CoV-2 感染期间骨髓细胞介导的肺损伤的数字病理学
基本信息
- 批准号:10348996
- 负责人:
- 金额:$ 24.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-08 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcuteAcute Respiratory Distress SyndromeAgreementAlgorithmic AnalysisAnimal ModelAntibodiesAntibody TherapyAntibody-Dependent EnhancementAreaBenchmarkingCOVID-19COVID-19 complicationsCOVID-19 patientCOVID-19 therapeuticsCellsCessation of lifeClinicalComplement ActivationDataDevelopmentDiseaseDisease OutcomeDisease ProgressionEndotheliumFutureHamstersHumanImage AnalysisImmuneImmunologic MonitoringInflammationInflammatoryInflammatory InfiltrateInflammatory ResponseInstitutionInterventionLaboratoriesLeadLungMalignant NeoplasmsMeasuresMediatingMesocricetus auratusModelingMonoclonal AntibodiesMyelogenousMyeloid CellsNew EnglandOutcomePathologicPathologyPathway interactionsPersonsPharmaceutical PreparationsPhase II Clinical TrialsPopulationPre-Clinical ModelPreventivePulmonary PathologyReagentReproducibility of ResultsResearch DesignSARS-CoV-2 infectionSARS-CoV-2 pathogenesisSolid NeoplasmStandardizationTestingTherapeutic antibodiesTimeTissuesTitrationsTreatment EfficacyTriageTumor-infiltrating immune cellsVaccinesVariantViral Load resultcellular targetingdigital pathologydrug candidatedrug efficacyefficacy trialimmunohistochemical markersimprovedinhibitorlung injurymacrophagemultiple omicsneutralizing antibodyneutrophilnonhuman primatenovel therapeuticsnovel vaccinespathogenphosphatidylinositol 3-kinase gammapre-clinicalpromoterquantitative imagingresponsesmall molecule inhibitortargeted treatmenttherapy outcometooltraffickingvaccination outcomevaccine candidatevaccine efficacyvaccine-induced antibodies
项目摘要
Project Summary
Macrophages and neutrophils are implicated in SARS CoV-2 pathogenesis in people and non-human primates
but their contribution to SARS CoV-2 pathology in the hamster model is poorly defined. We hypothesize that
myeloid cells can be targeted therapeutically to improve COVID-19 outcomes and we will explore this in the
hamster model of COVID-19 infection. The hamster model is a tractable small animal model for COVID-19 that
models severe clinical disease in humans yet, variations in study design, tissue and time-points assessed limit
cross-institutional comparison of results and result reproducibility. We propose that quantitative image analysis
can be used to effectively monitor immune cell infiltrates and define mechanisms of disease progression in the
hamster model, but pathologic correlates of clinical disease need to be established. More broadly, there is a
need to standardize quantitative pathologic endpoints in animal models of SARS CoV-2 infection in order to
benchmark study quality, improve cross-institutional comparison of data, validate cellular targets, and assess
therapeutic efficacy such that potential drugs for SARS CoV-2 can rapidly advance. We will use quantitative
image analysis to explore mechanisms of myeloid mediated tissue damage such as antibody dependent
enhancement of disease (ADE) and the PI3K inflammatory pathway. Using the Syrian hamster model and digital
pathology we will assess the relative contribution of myeloid cell populations to disease pathology in SARS CoV-
2 infection and explore mechanisms of myeloid-mediated lung damage. We will develop image analysis tools to
quantify inflammatory infiltrates and define pathologic correlates of clinical disease in the hamster model of SARS
CoV-2 infection. We will perform titration studies to establish pathologic endpoints that correlate with clinical
disease and viral load to better understand vaccine and therapeutic outcomes in this model. We will also define
mechanisms of myeloid-mediated tissue damage in SARS CoV-2 infected hamsters using an optimized image
analysis toolset. We will explore subtherapeutic monoclonal Ab (MAb) treatment and non-protective levels of
vaccine-induced neutralizing antibodies to establish pathologic metrics for assessing iADE and use a PI3K-γ
inhibitor currently in Phase II clinical trials for solid tumors, to determine whether myeloid cell trafficking can be
modulated by inhibiting the PI3K-γ pathway. Development of validated and standardized quantitative image
analysis end-points that correlate with clinical and virologic control in hamsters will more rapidly advance pre-
clinical drug and vaccine efficacy trials for development of SARS CoV-2 therapeutics and preventives. These
tools can also be used to explore pathologic mechanisms of disease in COVID-19.
1
项目摘要
巨噬细胞和中性粒细胞参与SARS CoV-2在人类和非人类灵长类动物中的发病机制
但它们在仓鼠模型中对SARS CoV-2病理学的作用尚不清楚。我们假设
骨髓细胞可以在治疗上靶向改善COVID-19的结果,我们将在
COVID-19感染的仓鼠模型。仓鼠模型是一种易于处理的COVID-19小动物模型,
在人类中模拟严重的临床疾病,研究设计、组织和时间点的变化评估限制
结果的跨机构比较和结果再现性。我们建议定量图像分析
可用于有效监测免疫细胞浸润,并确定疾病进展的机制,
仓鼠模型,但临床疾病的病理相关性需要建立。更广泛地说,
需要标准化SARS CoV-2感染动物模型的定量病理终点,
基准研究质量,改善数据的跨机构比较,验证细胞靶点,并评估
因此,SARS CoV-2的潜在药物可以迅速发展。我们将使用定量
图像分析探讨骨髓介导组织损伤机制
疾病增强(ADE)和PI 3 K炎症通路。使用叙利亚仓鼠模型和数字
我们将评估骨髓细胞群体对SARS CoV疾病病理学的相对贡献,
2感染,探讨骨髓介导的肺损伤机制。我们将开发图像分析工具,
在SARS仓鼠模型中定量炎性浸润并确定临床疾病的病理相关性
CoV-2感染。我们将进行滴定研究,以确定与临床相关的病理终点。
疾病和病毒载量,以更好地了解该模型中的疫苗和治疗结果。我们还将定义
利用优化图像研究SARS CoV-2感染仓鼠骨髓介导的组织损伤机制
分析工具集。我们将探讨亚治疗性单克隆抗体(MAb)治疗和非保护性水平的
疫苗诱导的中和抗体,以建立评估iADE的病理指标,并使用PI 3 K-γ
抑制剂目前在实体瘤的II期临床试验中,以确定髓系细胞运输是否可以
通过抑制PI 3 K-γ途径调节。开发经验证和标准化的定量图像
与仓鼠的临床和病毒学控制相关的分析终点将更快地提前,
临床药物和疫苗有效性试验,用于开发SARS CoV-2治疗和预防药物。这些
工具也可用于探索COVID-19疾病的病理机制。
1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amanda Martinot其他文献
Amanda Martinot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amanda Martinot', 18)}}的其他基金
Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters
用于定义仓鼠急性 SARS CoV-2 感染期间骨髓细胞介导的肺损伤的数字病理学
- 批准号:
10700811 - 财政年份:2022
- 资助金额:
$ 24.75万 - 项目类别:
Myeloid-Derived Suppressor Cells in Tuberculosis Granuloma Structure and Function
结核肉芽肿中骨髓源性抑制细胞的结构和功能
- 批准号:
10247081 - 财政年份:2020
- 资助金额:
$ 24.75万 - 项目类别:
Myeloid-Derived Suppressor Cells in Tuberculosis Granuloma Structure and Function
结核肉芽肿中骨髓源性抑制细胞的结构和功能
- 批准号:
10082741 - 财政年份:2020
- 资助金额:
$ 24.75万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 24.75万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 24.75万 - 项目类别: